title: Up-regulation of CXC chemokine receptor 4 expression in chronic atrial fibrillation patients with mitral valve disease may be attenuated by renin-angiotensin system blockers.
abstract: This study characterized CXC chemokine receptor 4 (CXCR4) expression in patients with mitral valve disease and chronic atrial fibrillation (AF). Forty-eight patients with chronic AF formed two groups based on whether they were treated with or without renin-angiotensin system (RAS) blockers (AF + RAS group; n = 25, or AF - RAS group; n = 23). The controls comprised 17 mitral valve disease patients with sinus rhythm (SR group). CXCR4 mRNA and protein levels in the left atria were significantly higher in the AF - RAS and AF + RAS groups than in the SR group. CXCR4 expression was significantly lower in the AF + RAS group than the AF - RAS group. More CD34(+) cells expressed CXCR4 in the AF - RAS and AF + RAS groups than in the SR group. Angiotensin II, collagen I and left atrial diameter significantly positively correlated with CXCR4 expression in the AF - RAS group. These results suggest that CXCR4 expression is up-regulated in chronic AF patients with mitral valve disease, is associated with atrial remodelling, and that these effects are attenuated by RAS blockers.
authors.affiliation: Department of Cardiology, The First Affiliated Hospital, Medical School of Zhejiang University, Hangzhou, China.
authors.forename: X X
authors.initials: XX
authors.lastname: Wang
authors.forename: F R
authors.initials: FR
authors.lastname: Zhang
authors.forename: J H
authors.initials: JH
authors.lastname: Zhu
authors.forename: X D
authors.initials: XD
authors.lastname: Xie
authors.forename: J Z
authors.initials: JZ
authors.lastname: Chen
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000378:metabolism; D003094:Collagen / Q000235:genetics / Q000378:metabolism; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D006325:Heart Atria / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D008943:Mitral Valve / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008944:Mitral Valve Insufficiency / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects* / Q000235:genetics
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D012333:RNA, Messenger; D019718:Receptors, CXCR4; D000804:Angiotensin II; D003094:Collagen